Related Experiment Video
Updated: Mar 27, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Resolution (and Late Recurrence) of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran
Abdul H Qazi1, Alan P Wimmer1, Kenneth C Huber1
1Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
Insights
Device-related thrombus (DRT) in WATCHMAN left atrial appendage closure devices can occur late. Novel oral anticoagulants (NOACs) like dabigatran may resolve DRT, but recurrence is possible.
Area of Science:
- Cardiology
- Medical Devices
- Pharmacology
Background:
- The WATCHMAN device is an alternative for stroke prevention in atrial fibrillation patients intolerant to warfarin.
- Left atrial device-related thrombus (DRT) is an infrequent complication of WATCHMAN implantation.
- Optimal treatment for DRT and the efficacy of novel oral anticoagulants (NOACs) remain undescribed.
Observation:
- A 69-year-old patient with atrial fibrillation developed DRT on her WATCHMAN device one year post-implantation.
- Transesophageal echocardiograms (TEE) showed initial DRT formation, resolution after 3 months of dabigatran and aspirin, and late recurrence 8 months later.
Findings:
- This case is the first to report successful WATCHMAN DRT treatment with a NOAC (dabigatran).
- Late DRT formation was observed, occurring after initial resolution with anticoagulation.
- Late recurrence of DRT was documented despite prior treatment.
Implications:
- WATCHMAN DRT can manifest late after implantation.
- NOACs, specifically dabigatran, demonstrate efficacy in resolving WATCHMAN DRT.
- Late recurrence of DRT is a possibility even after successful treatment with anticoagulation.
Abstract:
The WATCHMAN left atrial (LA) appendage closure system is an alternative therapy for stroke prevention in patients with atrial fibrillation who are intolerant to chronic oral anticoagulation with warfarin. Infrequently, LA device-related thrombus (DRT) has been suspected. Optimal treatment of DRT is not known, and the efficacy of novel oral anticoagulants (NOAC) in this setting has not been previously described. A 69-year-old woman with permanent atrial fibrillation underwent WATCHMAN device placement. A transesophageal echocardiogram (TEE) performed 45 days following implant revealed a well-seated device. A 1-year follow-up TEE revealed a 1.2 × 0.8 cm sized DRT on the LA aspect of the WATCHMAN device. She was prescribed dabigatran 150 mg po BID for 3 months and she remained on aspirin 325 mg per day. She returned approximately 4 months later (and several weeks after completing her 3-month course of dabigatran) for a repeat TEE, which revealed complete resolution of the DRT. A TEE was performed approximately 8 months later and revealed a new DRT measuring 1 cm in diameter on the LA aspect of the device. This is the first report of successful WATCHMAN DRT treatment with a NOAC, and the first report of late DRT recurrence following treatment to resolution with an anticoagulant. This case report demonstrates that (1) WATCHMAN DRT may form late following implantation, (2) DRT resolution is possible with NOACs, specifically dabigatran, and (3) late recurrence of DRT is possible, even after treatment to initial resolution with systemic anticoagulation.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Venous Thrombosis IV: Nursing Management

